Svelte Medical Systems
New Providence, US · Delaware corporation · 1 known investors
Founders & leadership
RC
Robert CroceExecutive
JD
Jack DarbyNamed on SEC filing
Board
SS
Somu SubramaniamBoard director
RF
Robert FlanaganBoard director
RD
Richard DakersBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$71.1M disclosed across 4 rounds · 2013–2021
▶$5.4MraisedMay 2021 · 17 investors · BiotechnologyRule 506(b)
▶$5.4MraisedMay 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CroceExecutive Officer, Director
- Somu SubramaniamDirector
- Richard DakersDirector
- Jack DarbyExecutive Officer, Director
- Robert FlanaganDirector
- Offering amount
- $10.8M
- Amount sold
- $5.4M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2017 · 10 investors · BiotechnologyRule 506(b)
▶$3MraisedNov 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phillip D. TorrenceExecutive Officer
- Mark A. KielekExecutive Officer
- Somu SubramaniamDirector
- Robert FlanaganDirector
- Richard DakersDirector
- Jack DarbyExecutive Officer, Director
- Robert CroceExecutive Officer, Director
- Timothy LashDirector
- Offering amount
- $52M
- Amount sold
- $3M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.3MraisedJul 2017 · 9 investors · BiotechnologyRule 506(b)
▶$12.3MraisedJul 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CroceExecutive Officer, Director
- Mark A. KielekExecutive Officer
- Phillip D. TorrenceExecutive Officer
- Somu SubramaniamDirector
- Richard DakersDirector
- Jack DarbyExecutive Officer, Director
- Timothy LashDirector
- Robert FlanaganDirector
- Nicholas ValerianiDirector
- Offering amount
- $15M
- Amount sold
- $12.3M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.4MraisedJul 2016 · 39 investors · BiotechnologyRule 506(b)
▶$50.4MraisedJul 2016 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark A. KielekExecutive Officer
- Robert FlanaganDirector
- Richard DakersDirector
- Phillip D. TorrenceExecutive Officer
- Somu SubramaniamDirector
- Michael CaponettoDirector
- Jack DarbyExecutive Officer, Director
- Robert CroceExecutive Officer, Director
- Offering amount
- $50.8M
- Amount sold
- $50.4M
- Sales commissions
- $430K
- Proceeds to insiders
- $1.4M
- Placement agents
- Piper Jaffray & Co.
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Svelte Medical Systems's investors?
- Svelte Medical Systems's investors include New Science Ventures.
- How much funding has Svelte Medical Systems raised?
- Svelte Medical Systems has disclosed $71.1M raised across 4 rounds.
- Where is Svelte Medical Systems headquartered?
- Svelte Medical Systems is headquartered in New Providence, US.